Last edition
News about "Midline Glioma "
The US Food and Drug Administration (FDA) has granted accelerated approval for Jazz Pharmaceuticals' Modeyso (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with H3 K27M-mutant diffuse midline glioma – a rare and highly aggressive brain tumour – with progressive disease following prior therapy.
Midline Glioma | 08/08/2025 | By Dineshwori | 222
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members